Isolated type 5 antimitochondrial autoantibodies are associated with a history of thrombocytopenia and fetal loss

Oliver-Miñarro, Desamparados; Sánchez‐Ramón, Silvia; Rodríguez‐Mahou, Margarita; Álvarez, Silvia; Fernández‐Cruz, Eduardo

doi:10.1016/j.fertnstert.2006.07.1535

Cited by 6 publications

(6 citation statements)

References 10 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenic role of anti‐phsophatidylethanolamine antibodies in pregnancy complications was supported by a study which showed that passive immunization of anti‐phosphatidylethanolamine in mice induced placental thrombosis and hemorrhage . Few cases described type 5 anti‐mitochondrial autoantibodies (M5‐type AMA) in patients with obstetrical adverse events, but larger studies are lacking . The non‐conventional APL are not included in APS diagnostic criteria and despite these association studies, physiopathological and drug intervention studies are needed to demonstrate the value of these various autoantibodies in patients with pregnancy failure…”

Section: Autoantibodies In Urm and Rifmentioning

confidence: 99%

Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?

Mékinian

Cohen

Alijotas‐Reig

et al. 2016

American J Rep Immunol

129

View full text Add to dashboard Cite

To describe and analyze the benefit of immunomodulatory drugs for recurrent miscarriages and implantation failures. The literature research was conducted in Medline, Embase and Cochrane Library concerning recurrent miscarriages and implantation failures and steroids, progesterone, intralipids, TNF-α antagonists, G-CSF, hydroxychloroquine, intravenous immunoglobulins, endometrial scratching. Using meta-analysis, modest benefit was found for progesterone to obtain a live birth, with odds ratio at 1.38 (95% CI: 1.07-1.77) and significant heterogeneity (P = 0.01, I(2) = 78%). In early ≥3 miscarriages, patients treated by TNF-α antagonists (adalimumab or etanercept; n = 17) combined with low-dose aspirin, heparin and intravenous immunoglobulins have a live births of 71% (12/17), vs 19% with aspirin+heparin (4/21) (P = 0.0026). Sixty-eight patients with unexplained recurrent miscarriage were randomized to receive either G-CSF (filgastrim, Neupogen, 1 μ/kg/day SC, n = 35) after the ovulation until the 9th weeks of gestation or placebo (n = 33). Among patients treated with G-CSF, 29/35 (82.8%) have live birth and 16/33 (48.5%) of controls (P = 0.006). Among 200 women with recurrent miscarriages and implantation failure treated with intralipids, the pregnancy rate was 52%, with pregnancy ongoing/live birth rate at 91%. The physiopathological rational for immunotolerance failure in this topic raise the need to demonstrate the efficacy of immunomodulatory drugs, define the patients subsets and develop treatment strategies.

show abstract

Section: Autoantibodies In Urm and Rifmentioning

confidence: 99%

Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?

Mékinian

Cohen

Alijotas‐Reig

et al. 2016

American J Rep Immunol

129

View full text Add to dashboard Cite

show abstract

“…Antibodies to mitochondria, which are rich in CL and are not normally exposed, were recently reported [201]. It was shown in the 1970s that exposure of heart mitochondria caused C activation [202,203].…”

Section: Introductionmentioning

confidence: 99%

“…Hinton suggested that aCL could be a secondary response to antigens exposed as a result of initial tissue injury [ 200 ]. Antibodies to mitochondria, which are rich in CL and are not normally exposed, were recently reported [ 201 ]. It was shown in the 1970s that exposure of heart mitochondria caused C activation [ 202 , 203 ].…”

Section: Introductionmentioning

confidence: 99%

Antiphospholipid antibodies: Paradigm in transition

Horstman

Bidot

et al. 2009

J Neuroinflammation

View full text Add to dashboard Cite

ObjectivesThis is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP.OrganizationAfter a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed.ConclusionThe current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.

show abstract

“…Even though the mechanisms underlying how the fetus escapes rejection by the maternal immune system are not known, it has been reported that 30% of women with RPL show fetal rejection caused by autoimmune factors (Figure 2) [5,12]. Autoimmune factors include various autoantibodies such as anti-phospholipid antibodies (APA), antinuclear antibodies (ANA) and anti-thyroid antibodies (ATA) [12]. Autoantibodies might cause growth inhibition of the trophoblast and pathogenic thrombosis.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, other cellular-antigen antibodies that are produced alongside antiphospholipid antibodies might contribute to thrombosis [15]. Accordingly, impaired blood supply to the fetus, placental infarction and fetal-growth retardation are observed in women with RPL [12]. However, the exact mechanisms for pregnancy loss due to antinuclear antibodies (ANA) and anti-thyroid antibodies (ATA) are poorly understood.…”

Section: Introductionmentioning

confidence: 99%